Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life

Sjoukje Lubberts, MD[1]; Harmke J. Groot, MD, PhD[2]; Ronald de Wit, MD, PhD[3]; Sasja Mulder, MD, PhD[4]; Johannes A. Witjes, MD, PhD[5]; J. Martijn Kerst, MD, PhD[6]; Gerard Groenewegen, MD, PhD[7]; Joop D. Lefrandt, MD, PhD[8]; Flora E. van Leeuwen, PhD[2]; Janine Nuver, MD, PhD[1]; Michael Schaapveld, PhD[2]; and Jourik A. Gietema, MD, PhD[1]

ABSTRACT

PURPOSE Testicular cancer (TC) treatment is clearly associated with cardiovascular morbidity and mortality. To enable development of preventive strategies for cardiovascular disease (CVD), we assessed cardiometabolic risk factors and quality of life (QoL) in TC survivors.

METHODS Incidence of coronary artery disease, myocardial infarction, and heart failure after TC treatment was assessed in a multicenter cohort comprising 4,748 patients treated at the age of 12-50 years between 1976 and 2007. Patients who had developed CVD and a random sample from the cohort (subcohort) received a questionnaire on cardiometabolic risk factors and QoL. A subgroup of responders in the subcohort additionally underwent clinical evaluation of cardiovascular risk factors.

RESULTS After a median follow-up of 16 years, 272 patients had developed CVD. Compared with orchidectomy only, cisplatin combination chemotherapy was associated with an increased CVD risk (hazard ratio [HR], 1.9; 95% CI, 1.1 to 3.1). Patients who were obese or a smoker at diagnosis (HR, 4.6; 95% CI, 2.0 to 10.0 and HR, 1.7; 95% CI, 1.1 to 2.4, respectively), developed Raynaud's phenomenon (HR, 1.9; 95% CI, 1.1 to 3.6) or dyslipidemia (HR, 2.8; 95% CI, 1.6 to 4.7) or had a positive family history for CVD (HR, 2.9; 95% CI, 1.7 to 4.9) had higher CVD risk. More TC survivors with CVD reported inferior QoL on physical domains than survivors who did not develop CVD. Of 304 TC survivors who underwent clinical evaluation for cardiovascular risk factors (median age at assessment: 51 years), 86% had dyslipidemia, 50% had hypertension, and 35% had metabolic syndrome, irrespective of treatment.

CONCLUSION Cardiovascular events in TC survivors impair QoL. Many TC survivors have undetected cardiovascular risk factors. We advocate early lifestyle adjustments and lifelong follow-up with low-threshold treatment of cardiovascular risk factors, especially in obese and smoking patients treated with platinum-based chemotherapy.

View Online Article

INTRODUCTION

Since the introduction of platinum-based chemotherapy, survival of patients with testicular cancer (TC) has improved substantially. Five-year survival rates now range between 99% for localized and 70% for poor risk disseminated disease.[1,2] In addition, the incidence of TC is increasing. As a result, the number of TC survivors is growing rapidly.[3] Therefore, prevention or early detection of late adverse effects of TC treatment has become increasingly important. Previous research has shown that TC treatment, particularly platinum-based chemotherapy, is associated with increased risk of cardiovascular morbidity and mortality, probably resulting from vascular damage.[4-7] The mechanisms behind vascular damage after TC treatment are not yet fully understood but may involve development of endothelial dysfunction. This association has been shown in vitro and in vivo.[8-11] Endothelial dysfunction is influenced by cardiovascular risk factors, and TC treatment has been shown to be associated with development of an unfavorable cardiovascular risk profile, including dyslipidemia, hypertension, insulin resistance, and overweight. The latter are all aspects of the metabolic syndrome, which may affect up to 25% of TC survivors treated with platinum-based chemotherapy.[5,12-16]

In this study, we evaluated risk factors for development of cardiovascular disease (CVD) after TC treatment. We assessed cardiometabolic risk factors at diagnosis and during

CONTEXT

Key Objective

How can we identify which patients with testicular cancer (TC) are at risk to develop cardiovascular disease (CVD) after treatment?

Knowledge Generated

Knowledge of CVD development after TC is relevant because CVD leads to decreased quality of life. Platinum-based chemotherapy, obesity, and smoking at diagnosis lead to increased CVD risk. Patients who developed Raynaud's phenomena after treatment or dyslipidemia during follow-up were at increased risk for CVD development.

Relevance *(M.A. Carducci)*

This manuscript reinforces the long term survivorship risks for TC survivors, many diagnosed as adolescent and young adults. Platinum-based chemotherapy increases the long term risk of vascular disease. Lifelong preventive care is warranted to reduce risk of CVD through known mitigation efforts.*

*Relevance section written by *JCO* Associate Editor Michael A. Carducci, MD.

follow-up, along with well-known adverse treatment effects such as hypogonadism and Raynaud's phenomenon. Our secondary objectives were to investigate the impact of CVD on quality of life (QoL) and determine the actual presence of cardiometabolic risk factors in a random sample of TC survivors. Previous major studies looked mostly at treatment associations with CVD risk and did not assess in depth the characteristics of TC survivors who developed CVD.[4-7,17] Our study is the first to investigate a possible association between early adverse treatment effects such as Raynaud's phenomena and subsequent CVD development.

METHODS

Study Design

Five large Dutch TC treatment centers participated in this study: University Medical Center Groningen (UMCG), Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital Amsterdam (NKI/AVL), Erasmus Medical Center Rotterdam (EMC), Radboud University Medical Center Nijmegen (RUMC), and University Medical Center Utrecht (UMCU; ClinicalTrials.gov identifier: NCT02276430). These hospitals provided access to the medical records of 4,748 patients with TC who had completed their treatments between 1976 and 2007. Their age at TC diagnosis ranged from 12 years to 50 years. Patients who developed CVD after TC were identified in regular oncological follow-up or through contact with their general practitioner, as reported previously.[18] CVD was defined as myocardial infarction, proven coronary artery disease (Common Terminology Criteria for Adverse Events version 4 [CTCAE-4]: grade 2 or higher, ICD10 I20-25), or congestive heart failure (CTCAE-4 grade 2 or higher, ICD-10 I50). CVD before TC diagnosis was considered an exclusion criterion for analysis as a CVD case. A case-cohort design was chosen

(Data Supplement [Box 1], online only) to reduce the number of medical records to be abstracted while maintaining statistical power.[19] Patients who developed CVD were compared with a hospital-stratified subcohort, comprising 15% of the cohort in the EMC, RUMC, and UMCU and 25% of the cohort in the coordinating hospitals NKI/AVL and UMCG, which was randomly selected from the base cohort. It consisted of 925 patients, of whom 54 developed CVD. We abstracted treatment data from the medical records for all patients in the base cohort who developed CVD (cases) and all patients in the hospital-stratified subcohort (from now on: subcohort patients). The medical records specified their primary TC treatment and any relapse or contralateral TC treatment .

All patients with TC underwent hemiorchidectomy. For early-stage seminoma, orchidectomy was usually followed by radiotherapy, mostly targeting infradiaphragmatic para-aortic, ipsilateral iliac, and inguinal lymph nodes, with doses ranging from 30 to 35 Gy.[20] From the mid-1980s, radiation doses gradually decreased to 26 Gy. Patients with stage II-IV seminoma and nonseminoma were most frequently treated with cisplatin-containing chemotherapy—initially with cisplatin, vinblastine, and bleomycin and since the mid-1980s with bleomycin, etoposide, and cisplatin.[21]

During 2015-2017, all patients in the base cohort who had developed CVD (cases) and all subcohort patients who were alive were invited to complete a risk factor questionnaire. The questionnaire assessed life style, use of medication, family history for CVD, QoL (measured by the SF-36),[22] and known adverse treatment effects (Raynaud's phenomenon, neurotoxicity, ototoxicity, and fatigue).[23] In total, 717 patients were invited to complete the questionnaire, including 190 with CVD. The questionnaire was completed by 120 of 190 patients with CVD (63%) and 447 of 717 subcohort patients

(62%) in total. Subcohort patients who completed the questionnaire and were younger than 40 years at TC diagnosis and younger than 75 years at inclusion were then invited to participate in a cardiometabolic assessment. A total of 304 subcohort patients participated in the cardiometabolic study assessment, of whom 18 (6%) had developed CVD. An overview of study participation rates and reasons for noninvitation or nonparticipation are shown in Figure 1. The medical ethics committee (UMCG) approved this study. All participants gave written informed consent.

Cardiometabolic Study Procedures

The cardiometabolic study assessment consisted of physical examination, including anthropometrics (weight, height, and waist/hip circumference) and blood pressure measurement. Patients could visit one of the participating hospitals or their general practitioner for the anthropometrics and blood pressure measurements while sending their fasting blood samples to a central laboratory (UMCG). Hypertension was defined as a systolic blood pressure ≥140 mmHg, a diastolic blood pressure ≥90 mmHg, or use of antihypertensive drugs.[24] A fasting blood sample was drawn to establish lipid profile, glucose levels, and hormonal status. Dyslipidemia was defined as a fasting total cholesterol ≥5.2 mmol/L (201 mg/dL), LDL ≥2.5 mmol/L (97 mg/dL), HDL <1.04 mmol/L (40.2 mg/dL), or triglycerides >4.5 mmol/L (399 mg/dL) or usage of lipid lowering medication.[25,26] Diabetes mellitus was defined as glucose ≥7.0 mmol/L (126 mg/dL) or use of blood glucose lowering medication and prediabetes as

glucose ≥5.6 to <7.0 mmol/L (101 mg/dL).[27] The metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III.[28] In the blood samples, biomarkers for endothelial function (von Willebrand factor), hemostasis (coagulation factor VIII, tissue plasminogen activator [t-PA], plasminogen activator inhibitor 1 [PAI-1], fibrinogen), and inflammation (high sensitivity C-reactive protein) were measured. This biomarker selection was based on earlier studies of our group.[9-11] Hypogonadism was defined as serum testosterone concentration <10 nmol/L and/or a LH concentration ≥10 U/L or testosterone use. All blood samples were drawn between 7:30 and 11:30 a.m. to limit circadian variation. A morning urine sample was tested for microalbuminuria, defined as 2.5-25 mg albumin per mmol creatinine. Macroalbuminuria was defined as >25 mg albumin per mmol creatinine.

Statistics

Associations of TC treatment and cardiovascular risk factors with CVD risk were assessed in multivariable Cox regression models and presented as hazard ratios (HRs). Time at risk started at the date of orchidectomy and ended at the date of diagnosis of the first CVD of interest for patients with CVD (myocardial infarction, coronary artery disease, or congestive heart failure [ICD-10 I20-25, I50]). Patients without CVD were censored at date of death, emigration, or last follow-up, whichever came first. Barlow's weights were used to adjust the partial likelihood function for case-cohort analysis[19,29] (Data Supplement [Box 2]). Regression

FIG 1. The numbers of enrolled patients in this study, including reasons for noninvitation or nonparticipation. [a]Cases: patients who developed cardiovascular disease. [b]Subcohort: patients in the random sample from the multicenter testicular cancer cohort. [c]Of whom 54 patients developed cardiovascular disease. [d]Of whom 30 patients developed cardiovascular disease. [e]Of whom 18 patients developed cardiovascular disease.

TABLE 1. Patient Characteristics and CVD Risk

	Patients With CVD		Subcohort				
Characteristic	No., Median	%/Range	No., Median	%/Range	HR	95% CI	P
Disease and treatment characteristics							
No.	272		925				
Description of cardiovascular events							
CVD							
Myocardial infarction[a]	174	64.0					
Coronary artery disease without myocardial infarction[a]	76	27.9					
Heart failure, nonischemic etiology[b]	22	8.1					
Age at first CVD diagnosis, years[c]	51.5	24.5-77.2					
<45	62	23.2					
45-55	117	43.8					
55-65	69	25.8					
>65	19	7.1					
Time from TC diagnosis until first CVD, years[c]	15.5	0.1-34.4					
0-1	8	3.0					
1-9	66	24.8					
10-19	114	42.7					
20-24	36	13.5					
≥25	43	16.1					
Vital status at the time of invitation for study participation							
Alive	203	74.6					
Deceased[d]	67	24.6					
Died of CVD	30	11.0					
Died of described CVD (fatal event)	16	5.9					
Emigrated	2	0.7					
Treatment characteristics and CVD risk							
Age at TC diagnosis, years							**<.001**
Median	35.6		30.7				
Range	16.7-49.8		14.7-49.9				
14-30	73	26.8	434	46.9	1	Ref	
30-39	110	40.4	354	38.3	2.0	1.4 to 2.9	
40-49	89	32.7	137	14.8	4.1	2.7 to 6.3	
Histology							.23
Seminoma	121	44.5	358	38.7	1	Ref	
Nonseminoma	151	55.5	567	61.3	1.2	0.9 to 1.8	
Treatment period							.25
1976-1985	124	45.6	183	19.8	1	Ref	
1986-1995	95	34.9	304	32.9	0.7	0.5 to 1.1	
1996-2007	53	19.5	438	47.4	0.8	0.5 to 1.2	
Cumulative TC treatment							**.003**
Orchidectomy only	37	13.6	180	19.5	1	Ref	
Radiotherapy	88	32.4	272	29.4	1.1	0.6 to 1.9	
Chemotherapy	122	44.9	413	44.6	1.9	1.1 to 3.1	
Radiotherapy + chemotherapy	25	9.2	60	6.5	2.5	1.2 to 5.1	
Radiotherapy (primary, relapse, or contralateral tumor treatment)[e]							.37
No	159	58.5	594	64.2	1	Ref	
Yes	113	41.5	331	35.8	1.2	0.7 to 1.9	
Subdiaphragmatic only	94	34.6	306	33.1	1.1	0.7 to 1.7	
Supradiaphragmatic + subdiaphragmatic	18	6.6	24	2.6	1.9	0.7 to 4.4	
Chemotherapy (primary, relapse, or contralateral tumor treatment)[f]							**<.001**
No	125	46.0	452	48.9	1	Ref	
Yes	147	54.0	473	51.1	2.0	1.3 to 3.1	
Platinum-containing[f,g]	136	50.0	450	48.6	2.0	1.3 to 3.0	
Cardiovascular risk factors at TC diagnosis and CVD risk							
Weight at TC diagnosis							**<.001**
Normal weight (BMI ≤25 kg/m^2)	147	53.9	622	67.2	1	Ref	

(continued on following page)

TABLE 1. Patient Characteristics and CVD Risk (continued)

	Patients With CVD		Subcohort				
Characteristic	No., Median	%/Range	No., Median	%/Range	HR	95% CI	P
Overweight (BMI 25-30 kg/m^2)	91	33.9	257	27.8	1.2	0.7 to 1.7	
Obesity (BMI >30 kg/m^2)	34	12.2	46	5.0	4.6	2.0 to 10.0	
Smoking at TC diagnosis							**.002**
No	110	40.4	512	55.4	1	Ref	
Yes	162	59.6	413	44.6	1.7	1.1 to 2.4	
Data resulting from study questionnaire							
Completed questionnaires (n)	120		447				
Treatment toxicities and CVD risk[h]							
Raynaud's phenomenon	34	28.8	79	17.9	1.9[i]	1.1 to 3.6	**.034**
Only temporarily	9	7.5	21	4.7			
Persisting complaints	25	20.8	58	13.0			
Neurotoxicity	46	38.3	134	30.0	1.3[i]	0.8 to 2.3	.32
Only temporarily	13	10.8	48	10.7			
Persisting complaints	33	27.5	86	19.2			
Hearing problems							
Tinnitus	21	17.5	60	13.4	1.3[i]	0.7 to 2.3	.48
Hearing loss	16	13.3	36	8.1	0.9[i]	0.4 to 2.0	.83
Unilateral	7	5.8	7	1.6			
Bilateral	9	7.5	29	6.5			
Cardiovascular risk factors during follow-up and CVD risk[j]							
Hypertension	25	20.8	99	22.1	1.2[i]	0.7 to 2.0	.49
Dyslipidemia	29	24.2	70	15.7	2.8[i]	1.6 to 4.7	**<.001**
Diabetes mellitus	7	5.8	21	4.7	1.4[i]	0.5 to 3.5	.52
Family history and CVD risk[k]							
Family history of any CVD	76	63.3	196	43.9	2.9	1.7 to 4.9	**<.001**
Family history of cardiac disease	44	36.7	86	19.2	2.7	1.6 to 4.5	**<.001**

NOTE. All *P* values are for heterogeneity and corrected for age at diagnosis of TC. Bold indicates significant *P* values <.05.

Abbreviations: CVD, cardiovascular disease; HR, hazard ratio; ref, reference; TC, testicular cancer.

[a]Forty patients (16%) developed heart failure after myocardial infarction or coronary artery disease.

[b]These patients developed heart failure because of nonischemic causes: due to valvular disease (n = 7), heart rhythm disorders (n = 2), or cardiomyopathy (n = 1); in 12 patients underlying pathophysiology was unknown.

[c]Of five patients, the date of the cardiovascular event was unspecified and could not be retrieved from the medical records of the hospital or general practitioner. For these patients, age and timing after TC diagnosis could not be calculated.

[d]Cause of death was unknown in nine of the 67 dead patients (13.4%).

[e]HRs are corrected for administration of chemotherapy.

[f]HRs are corrected for administration of radiotherapy and BMI.

[g]Cisplatin or carboplatin-containing chemotherapy regimens.

[h]Treatment toxicities developed <1 year after TC treatment as reported in the questionnaire.

[i]Corrected for age at TC diagnosis and chemotherapy treatment (yes/no) in a multivariate Cox analysis.

[j]For patients with CVD, only risk factors developed before diagnosis of the first CVD were taken into account.

[k]Family history was reported in the patient questionnaire and considered positive when one or more first-degree family members developed respectively any CVD (including myocardial infarction, coronary disease, heart failure, sudden cardiac death, peripheral artery disease, cardiac arrythmias, cerebral vascular events, valvular heart disease, thromboembolisms, or aortic aneurysms) or cardiac disease (myocardial infarction, coronary disease, heart failure, or sudden cardiac death) before the age of 65 years.

analyses were adjusted for age at TC diagnosis. Cardiovascular risk factors which occurred during follow-up were modeled as time varying covariates. Missing baseline data on cumulative treatment and cardiovascular risk factors at diagnosis were handled by performing multiple imputation by chained equations (Data Supplement [Box 2]). Missing information from the questionnaires was handled by introducing a dummy variable in the model. Competing risk analysis was performed using death due to other causes than CVD as competing event.[30] Differences in QoL were assessed using unweighted linear regression with each scalar response to the items of the QoL questionnaire treated as a separate dependent variable, corrected for age at completion of the questionnaire, years between TC diagnosis, and completion of the questionnaire and years after CVD (which was zero for noncases). *P* values ≤.05 were considered significant. STATA statistical software (version SE13, StataCorp, College Station, TX) was used for analysis.

TABLE 2. Burden of CVD: Fatigue Scores and Quality of Life

	Patients With CVD (n = 120)			Subcohort Patients Without CVD (n = 417)		
Characteristic	Median (range)			Median (range)		
Age at completion of questionnaire, years	61 (41-85)			52 (27-79)		
Time after TC diagnosis, years	27 (8-40)			19 (7-38)		
Time after CVD diagnosis, years	8 (0-31)			—		
	Median (IQR)	Mean (SE)		Median (IQR)	Mean (SE)	P
Fatigue score	15 (7-21)	15 (0.7)		9 (6-16)	12 (0.3)	**.003**
Quality of life (scale scores)						
Physical functioning	80 (55-95)	72 (2.3)		95 (85-100)	89 (0.9)	**<.001**
Social functioning	88 (63-100)	82 (2.1)		100 (75-100)	87 (1.0)	**.01**
Role limitations due to physical health	100 (25-100)	70 (3.7)		100 (100-100)	85 (1.5)	**.001**
Role limitations due to emotional health	100 (100-100)	83 (3.1)		100 (100-100)	88 (1.5)	.18
Mental health	80 (68-92)	77 (1.7)		84 (72-88)	79 (0.8)	.11
Energy and vitality	65 (45-80)	62 (2.1)		70 (56-80)	68 (1.0)	**.002**
Bodily pain	90 (68-100)	80 (2.0)		100 (80-100)	88 (1.0)	**.036**
General health	55 (35-70)	54 (2.1)		70 (55-85)	68 (1.0)	**<.001**

NOTE. *P* values were corrected for age at completion of questionnaire, years between TC diagnosis, and completion of the questionnaire and years after CVD (which was 0 for subcohort patients without CVD) using a linear regression model. Items that were left blank (missing data) were not taken into account when calculating scale scores. Hence, scale scores represent the average for all items in the scale that the respondent answered (scale scores range from 0 to 100). Bold indicates significant *P* values <.05.
Abbreviations: CVD, cardiovascular disease; TC, testicular cancer.

RESULTS

Patients With CVD

After a median follow-up of 16.1 years (IQR, 9.7-24.5 years; range, 0-38.5 years), 272 TC survivors in the study population of 4,748 patients had developed CVD: 64% of them had experienced a myocardial infarction and 28% had coronary artery disease without infarction (Table 1). Of these patients, 16% developed heart failure afterward. Of the CVD events, 6% were fatal (n = 16).

Impact on QoL

Of the TC survivors who completed the risk factor questionnaire (n = 537; Fig 1), those who developed CVD after TC treatment reported a lower QoL on several domains than TC survivors without CVD (Table 2). TC survivors with CVD reported lower physical functioning (median score, 80 [IQR, 55-95] compared with 95 [IQR, 85-100] in subcohort patients without CVD, *P* < .001), which was accompanied by role limitations because of physical health. TC survivors with CVD also reported less energy and vitality, experienced more bodily pain (*P* = .002 and *P* = .036, respectively), and had a lower general health score than the TC survivors without CVD (*P* < .001). Furthermore, TC survivors who developed CVD reported more fatigue than patients who did not (*P* < .003). Social and mental health was not impaired in TC survivors with CVD.

Risk Factors Associated With CVD Development

Compared with orchidectomy only, treatment with chemotherapy was associated with increased CVD risk (HR, 1.9; 95% CI, 1.1 to 3.1) and when patients also received radiotherapy, this risk further increased (HR, 2.5; 95% CI, 1.2 to 5.1). Treatment with radiotherapy only was not associated with CVD risk (HR, 1.1; 95% CI, 0.6 to 1.9; Table 1).

TC survivors with CVD were older at TC diagnosis than subcohort patients (median age, 35.6 *v* 30.7 years; *P* < .0001; Table 1). Presence of obesity at TC diagnosis (HR, 4.6; 95% CI, 2.0 to 10.0) and smoking at TC diagnosis (HR, 1.7; 95% CI, 1.1 to 2.4) was associated with increased CVD risk (Table 1).

Analysis of raw data (without imputation of missing variables), and analysis only including patients with complete data, did not notably change the results (Data Supplement [Tables 1, 2a, and 2b]). Competing risk analysis using death due to other causes than CVD as competing event resulted in estimates pointing in the same direction (Data Supplement [Table 3]). There were no significant differences in baseline characteristics between patients participating in the study questionnaire and patients who did not participate (Data Supplement [Table 4]).

TC survivors who developed dyslipidemia during follow-up had an increased CVD risk (HR, 2.8; 95% CI, 1.6 to 4.7). Patients who reported a positive family history for CVD were

TABLE 3. Cardiovascular Risk Factors in Subcohort Members Who Participated in the Study Visits for Cardiometabolic Assessment

Characteristic	No., Median	%/Range
Total number of subcohort members	304	
Follow-up duration at study visit, years	21.8	7.9-39.0
Age at study visit, years	51.1	27.2-74.3
Medication use		
Antihypertensive drugs	72	23.7
Lipid-lowering drugs	47	15.5
Diabetic drugs	15	4.9
Testosterone suppletion	24	7.9
Cardiovascular risk factors		
Current smoker	45	15.0
Hypertension	150	49.5
Dyslipidemia[a]	260	85.5
High LDL (≥2.5 mmol/L)	223	82.0
Low HDL (≤1.04 mmol/L)	57	20.7
High triglycerides (>4.5 mmol/L)	9	3.3
High total cholesterol (≥5.2 mmol/L)	151	54.9
Diabetes[a]	28	9.2
Diabetes mellitus or prediabetes[a]	122	40.1
Overweight (BMI > 25)	196	64.5
Obesity (BMI > 30)	35	11.5
Metabolic syndrome	107	35.2
Anthropometrics		
BMI, kg/m^2	25.9	18.1-36.2
Waist circumference, cm	96	71-131
Waist/hip ratio	1.0	0.8-1.2
Gonadal function		
Testosterone, nmol/L[b]	14.6	0.7-55.4
LH, U/L[b]	7.3	0.4-46.6
Hypogonadism	103	34
Proteinuria and renal function		
Microalbuminuria	20	7.0
Macroalbuminuria	5	1.8
Urine albumin, mg/L	3.0	0.4-607.8
Urine albumin-creatine ratio, mg/mmol	0.4	0-71.6
Biomarkers[c]		
High vWF (>150%)	29	13
High FVIII (>150%)	47	21
High Hs-CRP (>5.0 mg/L)	27	12
High t-PA (>10 μg/L)	139	63
High PAI-1 (>43 μg/L)	61	28
High fibrinogen (>4.0 g/L)	16	7

Abbreviations: FVIII, coagulation factor VIII; Hs-CRP, high sensitivity C-reactive protein; LH, luteinizing hormone; PAI-1, plasminogen activator inhibitor 1; t-PA, tissue plasminogen activator; vWF, von Willebrand factor.
[a]Twenty-seven missing: Could not be assessed because of nonfasting blood samples. Use of lipid-lowering medication was also assumed to indicate the presence of dyslipidemia.
[b]Patients using testosterone suppletion excluded.
[c]The biomarkers could not be measured in all participating centers and, therefore, were missing in a part of the participants. The expressed percentages refer to the percentages of performed measurements, excluding missing values.

more prone to develop CVD (HR, 2.9; 95% CI, 1.7 to 4.9). Patients who had developed Raynaud's phenomenon after TC treatment seemed to have a higher risk of developing CVD (HR, 1.9; 95% CI, 1.1 to 3.6), correcting for administration of chemotherapy (Table 1).

Study Visit for Cardiometabolic Assessment

The cardiometabolic assessment (304 patients participating) took place at a median follow-up duration of 22 years after TC diagnosis (range, 8-39 years) and a median age of 51 years (range, 27-74 years; Table 3). Participants often had hypertension (50%), of which 48% was untreated. The prevalence of dyslipidemia was 86%, of which 82% was untreated. Dyslipidemia mostly presented as high LDL (82%) and/or high total cholesterol (55%). Prediabetes was also prevalent: 40% of the participants had a high fasting glucose. Of the participating TC survivors, 35% met the criteria for metabolic syndrome. Hypogonadism was present in 34%. Patients treated with orchidectomy only rarely reported Raynaud's phenomenon (Table 4).

Most cardiovascular risk factors were equally present in patients treated with orchidectomy only and in patients treated with chemotherapy or radiotherapy; only microalbuminuria was more frequently present in patients treated with chemotherapy (Table 4).

Prevalence of cardiovascular risk factors generally increased with increasing age at the time of the study visit (Data Supplement [Table 5]). However, the prevalence of dyslipidemia was already 82% in patients younger than 40 years, which was similar to the prevalence among the oldest subcohort members (81% in patients older than 60 years).

At the study visit, biomarkers for endothelial dysfunction, low-grade inflammation, and hemostasis were more often elevated (Table 3), especially t-PA and PAI-1 (63% and 28% respectively). Compared with survivors who had not developed metabolic syndrome, more TC survivors with metabolic syndrome had high t-PA (81% v 51%; P < .001), high PAI-1 (44% v 17%; P < .001), and high fibrinogen (18% v 3%; P = .005).

DISCUSSION

In this large case-cohort study with long-term follow-up, we studied risk factors contributing to the development of serious cardiovascular morbidity in TC survivors. Besides having been treated with platinum-based chemotherapy, obesity and smoking at the start of treatment, development of Raynaud's phenomenon or dyslipidemia after treatment, and a family history of CVD were important risk factors. We also studied the QoL of TC survivors. Although previous studies in unselected TC survivors showed similar health-related QoL compared with the general population,[31] our study showed that the development of CVD after TC treatment clearly affects the survivors' QoL: patients who

TABLE 4. Presence of Treatment Toxicity and Cardiovascular Risk Factors in Subcohort Members According to Treatment Modality (n = 304)

Characteristic	Chemotherapy	Radiotherapy	Orchidectomy Only	P
No.	159	76	69	
Age at study visit for cardiometabolic assessment, years, median (range)	48 (27.2-74.3)	53 (34.3-71.1)	53 (29.6-69.2)	**<.001**
Treatment toxicities developed <1 year after testicular cancer treatment, No. (%)				
Raynaud's phenomena	48 (30)	5 (6)	3 (4.3)	**<.001**
Only temporarily	15 (9)	1 (1)	0 (0)	
Persisting complaints	33 (21)	4 (5)	3 (4.3)	
Neurotoxicity	77 (48)	12 (16)	6 (8.7)	**<.001**
Only temporarily	32 (20)	2 (3)	0 (0)	
Persisting complaints	45 (28)	10 (13)	6 (8.7)	
Hearing problems, persisting complaints				
Tinnitus	34 (21)	6 (8)	2 (3)	**.001**
Hearing loss[a]	20 (13)	4 (6)	0 (0)	**.001**
Cardiovascular risk factors at cardiometabolic study assessment, No. (%)				
Hypertension	86 (54)	33 (43)	31 (45)	.212
Dyslipidemia[b]	135 (85)	67 (88)	58 (84)	.507
Diabetes[b]	15 (9)	8 (11)	5 (7)	.417
(Pre)diabetes[b]	65 (41)	32 (42)	25 (36)	.424
Overweight (BMI >25)	97 (61)	56 (74)	43 (62)	.116
Obesity (BMI >30)	15 (9)	9 (12)	11 (16)	.362
Metabolic syndrome	58 (37)	28 (37)	21 (30)	.757
Proteinuria and renal function				
Microalbuminuria, No. (%)	20 (13)	4 (5)	1 (1)	**.018**
Macroalbuminuria, No. (%)	5 (3)	0 (0)	0 (0)	.115
eGFR, mL/min	82 (29-122)	86 (49-130)	85 (50-121)	.376
Gonadal function, No. (%)				
Hypogonadism	55 (35)	31 (41)	17 (25)	.165
Biomarkers, No. (%)[c]				
High vWF (>150%)	17 (14)	3 (5)	9 (20)	.081
High FVIII (>150%)	24 (21)	12 (21)	11 (23)	.920
High Hs-CRP (>5.0 mg/L)	8 (7)	12 (21)	7 (16)	**.016**
High t-PA (>10 μg/L)	58 (59)	43 (74)	28 (61)	.128
High PAI-1 (>43 μg/L)	35 (29)	15 (26)	11 (25)	.828
High fibrinogen (>4.0 g/L)	5 (4)	6 (10)	5 (11)	.162

NOTE. The chemotherapy category includes patients who were treated with chemotherapy, with or without radiotherapy. P values were calculated for categorical variables using chi-square tests and for continuous variables using one-way ANOVA tests because of a normal distribution. Bold indicates significant P values <.05.

Abbreviations: ANOVA, analysis of variance; eGFR, estimated glomerular filtration rate; FVIII, coagulation factor VIII; Hs-CRP, high sensitivity C-reactive protein; PAI-1, plasminogen activator inhibitor 1; t-PA, tissue plasminogen activator; vWF, von Willebrand factor.

[a]Both unilateral and bilateral hearing loss.

[b]Twenty-seven missing: Could not be assessed because of nonfasting blood samples. Use of lipid-lowering medication was also assumed to indicate the presence of dyslipidemia.

[c]The biomarkers could not be measured in all participating centers and, therefore, were missing in a part of the participants. The expressed percentages refer to the percentages of performed measurements, excluding missing values.

experienced CVD reported inferior QoL on physical domains compared with TC survivors who did not develop CVD.

In patients with TC who participated in the cardiometabolic study assessment, we observed a high prevalence of cardiovascular risk factors, which were often not previously identified and were thus untreated. This confirms the finding

of a recent study that showed a higher prevalence of hypertension and hypercholesterolemia in TC survivors compared with the general male population, even from the start of treatment.[17]

Of note, cardiovascular risk factors (except for microalbuminuria) were equally prevalent in patients treated with

chemotherapy, radiotherapy, or orchidectomy only. Patients with TC in our study seemed to develop cardiovascular risk factors irrespective of treatment modality, which suggests that platinum-based chemotherapy has limited influence on the development of these risk factors. The development of cardiovascular risk factors could also not be explained by factors such as the presence of hypogonadism. In addition, patients with TC appear to have an unfavorable cardiovascular risk profile even at the time of diagnosis.[11,16,17] In our study, being obese at TC diagnosis was an important risk factor for developing CVD after treatment (HR, 4.7; 95% CI, 2.4 to 9.3). Although obesity is a known independent cardiovascular risk factor in the general population, fat tissue may also act as a body reservoir for platinum, and obesity at TC diagnosis could thus be related to circulating platinum levels long after chemotherapy.

In our study, treatment with platinum-based chemotherapy almost doubled the risk of CVD development compared with orchidectomy only (HR, 1.9; 95% CI, 1.1 to 3.1). Previous studies showed that TC treatment with chemotherapy is associated with an approximately three-fold increased risk of CVD compared with TC survivors treated with orchidectomy only.[5,18] The exact role of bleomycin versus platinum could not be investigated in this study as both were mostly combined. From in vitro data, it is known that both agents induce alterations in endothelial cell function.[9] Circulating platinum levels remain detectable up to 20 years after chemotherapy.[32-36] Circulating platinum residuals may result in chronic endothelial activation and have been associated with known late effects such as hypertension.[32,35] Whether the amount of long-term circulating platinum is also associated with CVD events has not yet been investigated. Impaired renal function is an important determinant of long-term exposure to circulating platinum residuals and may cause higher platinum levels during a longer period of time, thus contributing to endothelial activation leading to CVD.[32] Development of Raynaud's phenomenon after treatment—which is a marker of compromised endothelial function[37]—was associated with a higher CVD risk. Another marker for endothelial activation is albuminuria, which was more prevalent in TC survivors treated with chemotherapy. Albuminuria coincides with higher vascular stiffness in TC survivors.[38] In our study, TC survivors with the metabolic syndrome had elevated t-PA, PAI-1, and fibrinogen levels than survivors without the metabolic syndrome. This indicates an active fibrinolytic system, which also contributes to atherosclerosis.[39-41]

We, therefore, suggest a future study to determine whether a combination panel, including markers of subclinical endothelial damage (presence of Raynaud's phenomenon, albuminuria, and fibrinolytic markers), could predict which patients are at increased cardiovascular risk.

Treatment with radiotherapy only was not associated with increased CVD risk. A previous study in TC survivors[18] and our current study suggest that supradiaphragmatic radiotherapy is associated with CVD, although on the basis of only 18 patients who received supradiaphragmatic radiotherapy.

Our study had several limitations that should be mentioned here. First, we made a cross-sectional assessment of cardiovascular risk factors, but the cardiovascular risk factors in patients who had developed CVD were derived only from questionnaires sent to the patients and their general practitioners. As a result, the information tended to be incomplete. For example, information on cardiovascular risk factors at TC diagnosis was often not mentioned in the patients' medical records (ie, information on BMI or presence of obesity was missing for 22% of the patients with CVD and for 26% of all subcohort patients). Second, some selection bias could have been present in our data as patients who experienced a higher disease burden could have been more inclined to participate in a study evaluating late adverse treatment effects. Because patients who were alive were invited for participation to the questionnaire, this resulted in selection bias on the basis of survival and age. Furthermore, discrepancies in cutoff values of cardiovascular risk factors exist between different countries.

An important strength is that this is the first study to thoroughly compare a large group of TC survivors who developed overt CVD to a large cohort. Until now, most studies have been epidemiological: to study their CVD risk, TC patients were compared to general population controls.[4-6,17,18] Furthermore, in our random sample of TC survivors, cardiovascular risk factors and biomarkers were measured, and most participants gave their consent for a future invitation for a follow-up study to assess the association between observed cardiovascular risk factors and development of CVD.

To confirm the effectiveness of stringent treatment of modifiable cardiovascular risk factors—such as being overweight or a smoker, having high lipid levels, hypertension or a high blood glucose level—on CVD risk in TC survivors, future prospective studies are needed. Smoking cessation might require extra attention since a recent study showed that Danish TC survivors treated with chemotherapy consume more tobacco than the general population.[42] Also of interest are studies to assess whether platelet aggregation inhibitors or statin-based, lipid-lowering therapy could prevent atherosclerosis development and signs of early vascular aging in TC survivors. These intervention studies are urgently needed; similar to adult childhood cancer survivors,[43] cardiovascular morbidity shortens the remaining lifespan of patients with successfully treated TC[4,7,44] and, as shown in this study, decreases their QoL.

In conclusion, TC survivors are at risk of developing CVD if they are treated with platinum-based chemotherapy, were obese or smoking at diagnosis, develop dyslipidemia during follow-up, had a positive family history of CVD, or develop Raynaud's phenomenon. TC survivors who develop CVD reported inferior QoL on physical domains compared with

survivors who did not develop CVD. Many TC survivors have a high burden of cardiometabolic risk factors. As soon as possible after diagnosis, these patients should be encouraged to adopt a healthy lifestyle: stop smoking, be physically active, and maintain healthy dietary habits. Lifelong follow-up with low-threshold treatment of cardiovascular risk factors is needed, especially in obese and smoking patients treated with platinum–based chemotherapy. As oncologists, we should be working together with other health care professionals toward improving the lifespan and QoL of these young men after we have treated them successfully for TC.

AFFILIATIONS

[1]Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
[2]Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands
[3]Department of Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands
[4]Department of Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands
[5]Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands
[6]Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands
[7]Department of Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands
[8]Department of Vascular Medicine, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands

CORRESPONDING AUTHOR

Jourik A. Gietema, MD, PhD, Department of Medical Oncology, University Medical Center Groningen, University of Groningen, PO Box 30001, 9700 RB, Groningen, the Netherlands; e-mail: j.a.gietema@umcg.nl.

EQUAL CONTRIBUTION

S.L., H.J.G., M.S., and J.A.G contributed equally to this work.

PRIOR PRESENTATION

Presented in part at the 2022 ASCO Annual Meeting, Chicago, IL, June 3-7, 2022.

SUPPORT

CLINICAL TRIAL INFORMATION

NCT02276430

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI https://doi.org/10.1200/JCO.22.01016.

AUTHOR CONTRIBUTIONS

Conception and design: Sjoukje Lubberts, Harmke J. Groot, Ronald de Wit, J. Martijn Kerst, Flora E. van Leeuwen, Michael Schaapveld, Jourik A. Gietema
Financial support: Flora E. van Leeuwen
Administrative support: Harmke J. Groot, Michael Schaapveld
Provision of study materials or patients: Harmke J. Groot, Ronald de Wit, Johannes A. Witjes, Gerard Groenewegen
Collection and assembly of data: Sjoukje Lubberts, Harmke J. Groot, Sasja Mulder, Johannes A. Witjes, J. Martijn Kerst, Gerard Groenewegen, Michael Schaapveld, Jourik A. Gietema
Data analysis and interpretation: Sjoukje Lubberts, Harmke J. Groot, Ronald de Wit, Gerard Groenewegen, Joop D. Lefrandt, Flora E. van Leeuwen, Janine Nuver, Michael Schaapveld, Jourik A. Gietema
Manuscript writing: All authors
Final approval of manuscript: All authors
Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT

REFERENCES

1. Beyer J, Collette L, Sauve N, et al: Survival and new prognosticators in metastatic seminoma: Results from the IGCCCG-update consortium. J Clin Oncol 39:1553-1562, 2021
2. Gillessen S, Sauve N, Collette L, et al: Predicting outcomes in men with metastatic nonseminomatous germ cell tumors (NSGCT): Results from the IGCCCG update consortium. J Clin Oncol 39:1563-1574, 2021
3. Sung H, Ferlay J, Siegel RL, et al: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209-249, 2021
4. Fosså SD, Gilbert E, Dores GM, et al: Noncancer causes of death in survivors of testicular cancer. J Natl Cancer Inst 99:533-544, 2007
5. Haugnes HS, Wethal T, Aass N, et al: Cardiovascular risk factors and morbidity in long-term survivors of testicular cancer: A 20-year follow-up study. J Clin Oncol 28:4649-4657, 2010
6. Kerns SL, Fung C, Monahan PO, et al: Cumulative burden of morbidity among testicular cancer survivors after standard cisplatin-based chemotherapy: A multi-institutional study. J Clin Oncol 36:1505-1512, 2018
7. Hellesnes R, Myklebust TA, Fossa SD, et al: Testicular cancer in the cisplatin era: Causes of death and mortality rates in a population-based cohort. J Clin Oncol 39:3561-3573, 2021 (suppl 15)
8. Nuver J, De Haas EC, Van Zweeden M, et al: Vascular damage in testicular cancer patients: A study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 23:247-253, 2010
9. Nuver J, Smit AJ, Sleijfer DT, et al: Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer. Eur J Cancer 40:701-706, 2004
10. Nuver J, Smit AJ, van der Meer J, et al: Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 23:9130-9137, 2005
11. Lubberts S, Boer H, Altena R, et al: Vascular fingerprint and vascular damage markers associated with vascular events in testicular cancer patients during and after chemotherapy. Eur J Cancer 63:180-188, 2016
12. Gietema JA, Meinardi MT, van der Graaf WTA, et al: Syndrome X in testicular cancer survivors. Lancet 357:228-229, 2001
13. de Haas EC, Oosting SF, Lefrandt JD, et al: The metabolic syndrome in cancer survivors. Lancet Oncol 11:193-203, 2010
14. Meinardi MT, Gietema JA, van der Graaf WTA, et al: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 18:1725-1732, 2000
15. Sagstuen H, Aass N, Fosså SD, et al: Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 23:4980-4990, 2005

16. de Haas EC, Altena R, Boezen HM, et al: Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 24:749-755, 2013

17. Lauritsen J, Hansen MK, Bandak M, et al: Cardiovascular risk factors and disease after male germ cell cancer. J Clin Oncol 38:584-592, 2020

18. van den Belt-Dusebout AW, Nuver J, de Wit R, et al: Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 24:467-475, 2006

19. Barlow WE, Ichikawa L, Rosner D, et al: Analysis of case-cohort designs. J Clin Epidemiol 52:1165-1172, 1999

20. Zagars GK, Babaian RJ: Stage I testicular seminoma: Rationale for postorchiectomy radiation therapy. Int J Radiat Oncol Biol Phys 13:155-162, 1987

21. Hanna NH, Einhorn LH: Testicular cancer—Discoveries and updates. N Engl J Med 371:2005-2016, 2014

22. Aaronson NK, Muller M, Cohen PD, et al: Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 51:1055-1068, 1998

23. Alberts M, Smets EMA, Vercoulen JHMM, et al: "Verkorte vermoeidheids-vragenlijst": Een praktisch hulpmiddel bij het scoren van vermoeidheid. Ned Tijdschr Geneeskd 141:1526-1530, 1997

24. Williams B, Mancia G, Spiering W, et al: 2018 ESC/ESH guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J 39:3021-3104, 2018

25. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel III). JAMA 285:2486-2497, 2001

26. Arnett DK, Blumental RS, Albert MA, et al: 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary. Circulation 140:e563-e595, 2019

27. Alberti KGMM, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diab Med 15:539-553, 1998

28. Grundy SM, Cleeman JI, Daniels SR, et al: Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112:2735-2752, 2005

29. Barlow WE: Robust variance estimation for the case-cohort design. Biometrics 50:1064-1072, 1994

30. Fine JP, Gray RJ: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999

31. Cappuccio F, Rossetti S, Cavaliere C, et al: Health-related quality of life and psychosocial implications in testicular cancer survivors. A literature review. Eur Rev Med Pharmacol Sci 22:645-661, 2018

32. Boer H, Proost JH, Nuver J, et al: Long-term exposure to circulating platinum is associated with late effects of treatment in testicular cancer survivors. Ann Oncol 26:2305-2310, 2015

33. Gietema J, Meinardi M, Messerschmidt J, et al: Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet 355:1075-1076, 2000

34. Brouwers EE, Huitema AD, Beijnen JH, et al: Long-term platinum retention after treatment with cisplatin and oxaliplatin. BMC Clin Pharmacol 8:7, 2008

35. Trendowski MR, El-Charif O, Ratain MJ, et al: Clinical and genome-wide analysis of serum platinum levels after cisplatin-based chemotherapy. Clin Cancer Res 25:5913-5924, 2019

36. Dikhoff TGMH, De Goeij JJM, Mcvie JG: Long-term body retention and tissue distribution of platinum in cisplatin treated cancer patients. J Radioanal Nucl Chem 236:81-86, 1998

37. Block JA, Sequeira W: Raynaud's phenomenon. Lancet 357:2042-2048, 2001

38. Stelwagen J, Lubberts S, Steggink LC, et al: Vascular aging in long-term survivors of testicular cancer more than 20 years after treatment with cisplatin-based chemotherapy. Br J Cancer 123:1599-1607, 2020

39. Vaughan DE: PAI-1 and atherothrombosis. J Thromb Haemost 3:1879-1883, 2005

40. Salomaa V, Stinson V, Kark JD, et al: Association of fibrinolytic parameters with early atherosclerosis: The ARIC study. Circulation 91:284-290, 1995

41. Song C, Burgess S, Eicher JD, et al: Causal effect of plasminogen activator inhibitor type 1 on coronary heart disease. J Am Heart Assoc 6:e004918, 2017

42. Kreiberg M, Bandak M, Lauritsen J, et al: Adverse health behaviours in long term testicular cancer survivors: A Danish nationwide study. Acta Oncol 60:361-369, 2021

43. Yeh JM, Ward ZJ, Chaudhry A, et al: Life expectancy of adult survivors of childhood cancer over 3 decades. JAMA Oncol 6:350-357, 2020

44. Lubberts S, Kruyt L, Steggink LC, et al: Life expectancy 20 years after cisplatin-based treatment for testicular cancer. J Clin Oncol 35, 2017 (suppl 15; abstr 4550)

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Ronald de Wit
Consulting or Advisory Role: Bayer, Astellas Pharma, Orion, Hengrui Medicine
Research Funding: Bayer (Inst)
Travel, Accommodations, Expenses: Bayer

Sasja Mulder
Uncompensated Relationships: MSD Oncology (Inst)

Johannes A. Witjes
Honoraria: Astellas Pharma, Beigene, Ferring, AstraZeneca, Janssen, MSD, Bristol Myers Squibb/Pfizer, Nucleix
Consulting or Advisory Role: Bristol Myers Squibb, MSD, Janssen Oncology, Oncodiag, BeiGene, Ferring, AstraZeneca, Asieris Pharmaceuticals, Photocure, UroGen Pharma

Jourik A. Gietema
Research Funding: Roche/Genentech (Inst), AbbVie (Inst), Siemens (Inst)

No other potential conflicts of interest were reported.